trending Market Intelligence /marketintelligence/en/news-insights/trending/rrbf6zbmer7n2x8mhw4zwg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

EyeGate Pharmaceuticals receives Nasdaq noncompliance notice

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


EyeGate Pharmaceuticals receives Nasdaq noncompliance notice

Eyegate Pharmaceuticals Inc. received a notice from the Nasdaq Stock Market for failing to meet the $1 minimum bid price listing requirement.

To regain compliance, the closing bid price of the company's common stock must reach at least $1 per share for a minimum of 10 consecutive business days. The Waltham, Mass.-based pharmaceutical company has 180 days, or until Sept. 17, to achieve compliance.

If EyeGate fails to meet compliance by the deadline, it may be granted a second 180-day compliance period.

The company previously received a Nasdaq noncompliance notice for failing to meet the listing requirement of a minimum $2.5 million shareholders equity.

EyeGate is a clinical-stage specialty pharmaceutical company which focuses on treating diseases and disorders of the eye.